US2012059067A1PendingUtilityA1

1-acetyl-5-hydroxyanthracene-9,10-dione for treatment of retinal disease

42
Individually held — no corporate assignee on recordPriority: Sep 24, 2007Filed: Nov 11, 2011Published: Mar 8, 2012
Est. expirySep 24, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Rafal A. Farjo
A61P 7/10A61P 35/00A61P 7/00A61K 31/122A61P 27/02A61P 29/00
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10-dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration topically. The composition may be administered topically to a subject's eye.

Claims

exact text as granted — not AI-modified
1 . A composition comprising:
 a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of an agent having the formula:   
       
         
           
           
               
               
           
         
         wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization; and 
         wherein the composition is prepared for administration topically. 
       
     
     
         2 . A method of treating a retinal disease in a subject, comprising:
 administering topically to the subject's eye a composition comprising a pharmaceutical carrier and an amount, therapeutically effective for the treatment of the retinal disease, of an agent having the formula:   
       
         
           
           
               
               
           
         
         wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization. 
       
     
     
         3 . The method of  claim 2 , wherein the retinal disease comprises age-related macular degeneration. 
     
     
         4 . The method of  claim 2 , wherein the retinal disease comprises endophthalmitis. 
     
     
         5 . The method of  claim 2 , wherein the retinal disease comprises retinal edema. 
     
     
         6 . The method of  claim 2 , wherein the retinal disease comprises diabetic macular edema. 
     
     
         7 . The method of  claim 2 , wherein the retinal disease comprises diabetic retinopathy. 
     
     
         8 . The method of  claim 2 , wherein the retinal disease is characterized by inflammation. 
     
     
         9 . The method of  claim 2 , wherein the retinal disease is characterized by angiogenesis. 
     
     
         10 . The method of  claim 2 , wherein the retinal disease is characterized by neovascularization.

Join the waitlist — get patent alerts

Track US2012059067A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.